title: [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
abstract: VAD regimen, combining vincristine, doxorubicin, and dexamethasone was given to 6 previously untreated and 4 treated patients with multiple myeloma. The response rate was obtained in 67% of previously untreated patients and in 50% of previously treated patients. In responders, a rapid improvement of clinical symptoms accompanied with a significant decrease in M-protein was observed. Patients with response to VAD therapy were received melphalan and prednisolone as maintenance. Response duration ranged between 4 months and 38 months. The infectious episodes were occurred in 36.8% patients but none of these was serious. The present results suggest that VAD regimen is useful as primary treatment for multiple myeloma when rapid control of disease is necessary.
authors.affiliation: Third Department of Internal Medicine, School of Medicine, Yamaguchi University.
authors.forename: Y
authors.initials: Y
authors.lastname: Fujii
authors.forename: Y
authors.initials: Y
authors.lastname: Nisimura
authors.forename: Y
authors.initials: Y
authors.lastname: Tanizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Azuno
authors.forename: K
authors.initials: K
authors.lastname: Yaga
authors.forename: Y
authors.initials: Y
authors.lastname: Hirosige
authors.forename: K
authors.initials: K
authors.lastname: Kaku
authors.forename: T
authors.initials: T
authors.lastname: Kaneko
authors.forename: N
authors.initials: N
authors.lastname: Matumoto
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin